Prosecution Insights
Prosecution Insights
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNG, MICAH PAUL | 1 | 55.1% | +29.8% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.6% |
| VALLE, ERNESTO | 1 | 56.0% | +41.3% |
| GEMBEH, SHIRLEY V | 1 | 63.1% | +33.8% |
| BERRIOS, JENNIFER A | 1 | 37.1% | +49.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17549307 | OCULAR INSERT CONTAINING A GLUCOCORTICOID | BERRIOS, JENNIFER A | 3d overdue |
| 18121256 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | GEMBEH, SHIRLEY V | 9d |
| 18706306 | PRODRUGS OF AXITINIB | VALLE, ERNESTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17549307 | OCULAR INSERT CONTAINING A GLUCOCORTICOID | BERRIOS, JENNIFER A | 3d overdue |
| 18121256 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | GEMBEH, SHIRLEY V | 9d |
| 18915988 | METHODS OF TREATING ALLERGIC CONJUNCTIVITIS | YOUNG, MICAH PAUL | — |
| 18824391 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | BASQUILL, SEAN M | — |
| 18706306 | PRODRUGS OF AXITINIB | VALLE, ERNESTO | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18915988 | METHODS OF TREATING ALLERGIC CONJUNCTIVITIS | YOUNG, MICAH PAUL | — | §102Other | Non-Final OA | — | Pending | Oct 15, 2024 |
| 18824391 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | BASQUILL, SEAN M | — | §103DP | Non-Final OA | — | Pending | Sep 04, 2024 |
| 18706306 | PRODRUGS OF AXITINIB | VALLE, ERNESTO | — | §102§103§112 | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18121256 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | GEMBEH, SHIRLEY V | 1615 | §102§103§112Other | Non-Final OA | 9d | Pending | Mar 14, 2023 |
| 17549307 | OCULAR INSERT CONTAINING A GLUCOCORTICOID | BERRIOS, JENNIFER A | 1613 | §103§112 | Final Rejection | 3d overdue | Pending | Dec 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial